Guillain-Barre Syndrome linked to SARS-CoV-2 infection – meta-analysis and literature review
Open Access
- 1 May 2023
- journal article
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 25 (1) , 40-56
Abstract
Background The novel coronavirus disease-2019 (COVID-19), which is caused by Severe Acute Respiratory Distress Syndrome coronavirus 2 (SARS-CoV2), was originally detected in Wuhan, China in December 2019. In this meta-analysis and literature review, we compared and summarized the clinical presentation, cerebrospinal fluid (CSF) and electromyography (EMG) findings and outcomes in SARS-CoV-2 patients with Guillain-Barre Syndrome (GBS) and its variants. Methods We conducted a literature review in February 2023 searching for terms “Guillain-Barre Syndrome and COVID-19", “SARS neurology”, “COVID-19 complications”. We used PubMed and Google Scholar databases inquiring case reports or series of cases published between April 1, 2020, and September 14, 2023. Results Of the 52 GBS cases 61,5% (n=32) were male and 39,5% (n=20) were female. The mean age was 57 years old. A total of 75% (n=33) patients presented acute inflammatory demyelinating polyneuropathy (AIDP) variant, 6,8% (n=3) presented acute motor axonal neuropathy (AMAN) variant, 15,9% (n=7) presented acute motor-sensory axonal neuropathy (AMSAN) variant. A total of 85,7% (n=42) of patients were diagnosed with albuminocytological dissociation. During the hospitalization, a total of 30,8% (n=16) required mechanical ventilation. A total of 61,5% (n=32) of patients were treated with a 5-day regimen of intravenous immunoglobulin (IVIG) in dose 0.4 g/kg/day. There were 46,1% (n=24) complete recoveries from GBS, 32,7% (n=17) partial recoveries and 9,6% (n=5) of patients did not respond to treatment. A total of 11,5% (n=6) of patients died. Conclusion It is crucial to follow patients with COVID-19 and GBS over time to estimate properly the efficacy of treatment and evaluate the real percentage of recovery and complications.Keywords
This publication has 60 references indexed in Scilit:
- COVID‐19–associated Guillain‐Barré syndrome: The early pandemic experienceMuscle & Nerve, 2020
- Post-infectious Guillain–Barré syndrome related to SARS-CoV-2 infection: a case reportJournal of Neurology, 2020
- Guillain-Barré syndrome following COVID-19: new infection, old complication?Journal of Neurology, 2020
- The neuroinvasive potential of SARS‐CoV2 may play a role in the respiratory failure of COVID‐19 patientsJournal of Medical Virology, 2020
- Nationwide study of therapeutic plasma exchange vs intravenous immunoglobulin in Guillain‐Barré syndromeMuscle & Nerve, 2020
- Plasma exchange for Guillain-Barré syndromeCochrane Database of Systematic Reviews, 2017
- The Challenge of Respiratory Dysfunction in Guillain-Barré SyndromeArchives of Neurology, 2001
- Anticipating Mechanical Ventilation in Guillain-Barré SyndromeArchives of Neurology, 2001
- Electrophysiological classification of guillain‐barré syndrome: Clinical associations and outcomeAnnals of Neurology, 1998
- Campylobacter jejuni infections and anti‐GM1 antibodies in guillain‐barré syndromeAnnals of Neurology, 1996